Next Oncology-Virginia

Fairfax, Virginia 22031

35 studies enrolling now · 52 studies all time

What they study most

Acute Myeloid Leukemia, Adenocarcinoma of Esophagus, Adenoid Cystic Carcinoma, Adult Disease, Adult Solid Tumor, Advanced Cancer, Advanced Metastatic Cancer, Advanced Solid Tumor, Advanced Solid Tumor, Adult, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, BRAF Gene Mutation

Studies at this site

• A Study of DM005 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of ASP1002 in Adults for Treatment of Solid Tumors — Recruiting now
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors — Recruiting now
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Recruiting now
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers — Recruiting now
• A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Recruiting now
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — Recruiting now
• A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors — Recruiting now
• A Study of PHST001 in Advanced Solid Tumors — Recruiting now
• A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases — Recruiting now
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC — Recruiting now
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors — Recruiting now
• FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC — Recruiting now
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — Recruiting now
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors — Recruiting now
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Recruiting now
• A 2-part Phase 1/2 Open-label Trial on ODM-212 — Recruiting now
• QTX3034 in Patients With KRAS G12D Mutation — Recruiting now
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors — Recruiting now
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors — Recruiting now
• A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors — Recruiting now
• A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies — Recruiting now
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers — Recruiting now
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 — Recruiting now
• A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 — Recruiting now
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers — Recruiting now
• A Study in Patients With Advanced Cancers — Recruiting now
• Study Of ATRN-119 In Patients With Advanced Solid Tumors — Completed
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Running, not enrolling
• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors — Stopped early
• First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors — Starting soon
• First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors — Starting soon
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors — Completed
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors — Running, not enrolling
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Running, not enrolling
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Running, not enrolling
• A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer — Running, not enrolling
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors — Running, not enrolling
• A Study of TAS3351 in NSCLC Patients With EGFRmt — Stopped early
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway — Stopped early
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination — Running, not enrolling
• Safety and Tolerability of Intravenous Administration of ICVB-1042 — Stopped early
• A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer — Completed